Cell line · CVCL_0132
Papers251
1 to 20 of 251
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Integrative Assessment of Teucrium Extracts: Phytochemical Profile, Nutritional-Mineral Composition, Biological Activities, and Toxicological Assessment In Vitro and In Vivo. | Chem Biodivers | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Cullin-5 RING E3 ligase limits CD8⁺ T-cell persistence and effector responses during chronic antigen stimulation. | Cancer Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Genotype-driven tumor ecosystems drive immune evasion and immunotherapy resistance in melanoma. | Mol Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Computational design of optimized and preferentially paired human TCR constant regions for improved T cell function. | Sci Adv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ImmTACs overcome cytotoxic T cell suppression. | Immunother Adv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Flavasperfurans A and B, Two New Asperfuran Derivatives From the Marine-Derived Fungus Aspergillus flavus. | Chem Biodivers | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Chemical Constituents of the Deep-Sea-Derived Fungus Talaromyces wortmannii and Their Ferroptosis Inhibitory Activity. | Chem Biodivers | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Transient histone deacetylase inhibition reveals cell type invariant and specific effects of chromatin decondensation on irradiation response. | Front Cell Dev Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Acquired Resistance to the PRMT5 Inhibitor Confers Collateral Sensitivity to MEK Inhibition in MTAP-Null Non-Small Cell Lung Cancer. | Biomolecules | 2026 | Its Methods give the RRID and name the line | PubMed | |
| AI-enabled discovery and biochemical optimization of minibinders targeting cancer cell-surface proteins. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Scalable generation of hematopoietic stem cell-engineered off-the-shelf mono-specific cytotoxic T cells targeting solid tumors. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Hallachrome, a marine anthraquinone, impairs cell proliferation by acting as a functional mitochondrial uncoupler in A375 melanoma cells. | Front Pharmacol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A stress-adaptive lipid kinase axis defines metabolic vulnerabilities in neuroendocrine prostate cancer. | Cancer Cell | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Stress-Adaptive Lipid Kinase Axis Defines Metabolic Vulnerabilities in Neuroendocrine Prostate Cancer. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Selective mRNA translation determines adaptative mutability of melanoma cells to anti-BRAF/MEK combination therapy. | EMBO Mol Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Metabolic buffering restricts phenotype switching in melanoma. | EMBO J | 2026 | Its Methods give the RRID and name the line | PubMed | |
| BET Inhibition Synergizes with RLR Signaling to Enhance Tumor Immunogenicity and T-cell Recognition. | Cancer Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A viral ORFeome library for systems-level genetic dissection of host-pathogen interactions. | Cell | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Engineered iMSCs delivering wild-type IL-2 achieve dose-sparing tumor control via CD25-dependent CD8+ T-cell activation. | BMC Med | 2026 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0132/papers